---
title: A real-world observation of patients with glioblastoma treated with a personalized
  peptide vaccine
date: '2024-08-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39127809/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240811182801&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Current treatment outcome of patients with glioblastoma (GBM) remains
  poor. Following standard therapy, recurrence is universal with limited survival.
  Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized
  peptide vaccine targeting tumor-specific neoantigens. All patients were treated
  within the scope of an individual healing attempt. Among all vaccinated patients,
  including 70 treated prior to progression (primary) and 103 treated after ...
disable_comments: true
---
Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after ...